Navigation Links
Promising Alzheimer's drug trialled in a large EU study
Date:12/9/2013

An extensive European study is currently investigating whether a drug used to treat high blood pressure may also help patients with Alzheimer's disease. The EU is investing almost 6 million euros on the project, in which Sahlgrenska Academy and Sahlgrenska University Hospital are responsible for Sweden's contribution.

The drug being trialled in the study, nilvadipine, is a well-proven treatment for high blood pressure. Research has shown that nilvadipine counters the formation of amyloid plaques in animal brains.

The drug is now to be trialled with 500 Alzheimer's patients in nine European countries.

"Should this clinical trial be successful, nilvadipine would become the first Alzheimer's drug that not only reduces the symptoms of the disease but also acts on its causes. This could dramatically reduce Europe's costs for caring for patients with this neurodegenerative disease," says Anne Brjesson-Hanson, a researcher at Sahlgrenska Academy, University of Gothenburg, who is leading the Swedish participation in the study.

The patients in the study will be treated with nilvadipine or a placebo (inactive substance) for eighteen months. Patients who are already being treated with drugs to relieve the symptoms of Alzheimer's will continue to take them as before. Follow-up and check-ups will be carried out at the memory clinic at Sahlgrenska University Hospital.

"We will carry out repeated tests on the patients to see whether there are changes in memory and cognition during the trial period," says Anne Brjesson-Hanson.

This major European research collaboration is called NILVAD, and is being coordinated from Trinity College in Dublin, Ireland. Research teams in the UK, France, Netherlands, Greece, Hungary, Italy and Germany are taking part alongside Ireland and Sweden.


'/>"/>

Contact: Anne Börjesson-Hanson
anne.borjesson@neuro.gu.se
University of Gothenburg
Source:Eurekalert

Page: 1

Related medicine news :

1. Promising results for Swedish cancer drug candidate
2. Drug Offers Promising Approach to Improve Outcome for Children with High-risk Leukemia
3. Drug offers promising approach to improve outcome for children with high-risk leukemia
4. Are probiotics a promising treatment strategy for depression?
5. The Therapist Development Center Now Awarding MSW Scholarships for Second Year MSW Students with the “Promising Futures in Clinical Social Work” Scholarship Program
6. Investigational PARP inhibitor promising in BRCA-related cancers
7. Bcureful® Helps Fund Promising Tuberous Sclerosis Complex Research Project at NYU Langone Medical Center
8. Amino acid with promising anti-diabetic effects
9. Doctor Utilizes Stem Cell Extracts with Promising Results
10. Johns Hopkins researchers find promising therapeutic target for hard-to-treat brain tumor
11. Back-To-School: PCA Predict A Promising Season For Asian American Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... Award-winning medical group Allied Anesthesia today announced ... chair for Orange County health care system CalOptima Friday. CalOptima announced its election ... Mark Refowitz’s term, which runs through June 30 of this year, until another ...
(Date:3/28/2017)... ... March 28, 2017 , ... In its ... Success website has recently developed and published an informational resource that addresses frequently ... based on common inquiries the site’s team of third party administrator (TPA) contributors ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... ... Carson Liu of SkyLex Advanced Surgical, Inc. is thrilled to offer the recently ... balloon procedure, and this procedure adds to SkyLex Advanced Surgical’s already comprehensive ...
(Date:3/28/2017)... ... , ... Oily skin is a common and unwelcomed occurrence in people of all ages, genders ... offer to the discussion of dealing with excess skin oil. “Oily skin is a challenge ... that can help remove the oily shine while keeping the skin fresh and clean,” says ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  Sanderling Ventures, portfolio ... Ethicon, a division of Johnson & Johnson. Torax manufactures ... the treatment of gastro-esophageal reflux disease (GERD). The ... (MSA) technology and the procedure is currently available ... Torax Medical was founded by Sanderling Ventures, ...
(Date:3/27/2017)... FinancialBuzz.com News Commentary  ... According to a new report by Arcview Market Research, the ... 34 percent to $6.7 billion and can be expected to grow at ... five years, from $6.7 billion in 2016, to $22.6 billion in 2021. ... to purchase cannabis without a doctor,s recommendation. Voters in California ...
(Date:3/27/2017)... 2017 The staggering cost of cancer treatment ... access to the latest treatment options against cancer. Even ... patients have inadequate or no health insurance and are ... Access to modern cancer treatment is almost non-existent for ... The mission statements of pharmaceutical and biotech companies ...
Breaking Medicine Technology: